<quotes>
[1] "Elasadek et al. (DOI: 10.1021/ ml100060m) now describe the synthesis and characterization of the peptide-conjugate prodrug of doxorubicin."
[2] "This prodrug is stable and has anti-proliferative effects in a PSA-specific prostate cancer cell line, making it a worthy candidate for further preclinical studies."
</quotes>

<EnglishVersionAnswer>
Prodrugs for prostate cancer were synthesized and characterized by Elasadek et al., including a peptide-conjugate prodrug of doxorubicin. This prodrug is stable and exhibits anti-proliferative effects in a prostate cancer cell line specific to the protein PSA, positioning it as a promising candidate for further preclinical research.
</EnglishVersionAnswer>

<ChineseVersionAnswer>
埃拉斯德克等人（DOI：10.1021/ ml100060m）现在描述了多柔比星肽偶联前药的合成与表征。这种前药稳定，对特定于前列腺癌细胞系的蛋白质PSA具有抗增殖作用，使其成为进一步预临床研究的有希望的候选药物。
</ChineseVersionAnswer>

<quotes>
[1] "Paruch et al. (DOI: 10.1021/ ml100051d) describe the synthesis of a series of pyrazolo-pyridimine scaffold inhibitors and subsequent characterization."
[2] "The authors used a functional in vivo screen to assess the efficacy of the small molecules and identified a particularly promising one, dinaciclib."
[3] "This drug is currently in phase II clinical trials."
</quotes>

<EnglishVersionAnswer>
Paruch等人（DOI：10.1021/ ml100051d）描述了一系列吡唑并吡啶骨架抑制剂的合成及其后续表征。他们使用功能性的体内筛选方法评估了这些小分子的有效性，并确定了一个特别有前景的分子，dinaciclib。该药物目前正在进行二期临床试验。
</EnglishVersionAnswer>

<ChineseVersionAnswer>
帕鲁奇等人（DOI：10.1021/ ml100051d）描述了一系列吡唑并吡啶骨架抑制剂的合成和后续表征。他们通过功能性体内筛选评估了这些小分子的作用效果，并确定了dinaciclib这一特别有前景的分子。该药物目前正在进行二期临床试验。
</ChineseVersionAnswer>

<quotes>
[1] "Heinrich et al. (DOI: 10.1021/ ml100044h) describe the discovery, structure-activity relationship analysis, and cocrystallization of novel allosteric inhibitors of the kinase activity of this enzyme."
[2] "Small molecule inhibitors of this enzyme suffer from cross-reactivity to the insulin receptor ATP-binding site because of the similarity to the kinase ATP-binding site."
[3] "Therefore, competitive inhibitors of kinase activity also potentially inhibit insulin receptor signaling."
[4] "Because the inhibitors described by the authors bind at an allosteric site, they do not impact insulin receptor signaling at physiological concentrations."
[5] "Therefore, these small molecules are useful as tools for dissecting activity and as starting points for therapeutics."
</quotes>

<EnglishVersionAnswer>
Heinrich等人（DOI：10.1021/ ml100044h）描述了发现、结构-活性关系分析以及该酶激酶活性新型旁侧抑制剂的结晶化。这类酶的小分子抑制剂因与激酶ATP结合位点相似而表现出对胰岛素受体ATP结合位点的交叉反应性。因此，竞争性激酶活性抑制剂也可能抑制胰岛素受体信号。由于作者描述的抑制剂在旁侧位点结合，它们在生理浓度下不会影响胰岛素受体信号传递。因此，这些小分子是用于分解活动和作为治疗起点的有用工具。
</EnglishVersionAnswer>

<ChineseVersionAnswer>
海因里希等人（DOI：10.1021/ ml100044h）描述了发现、结构-活性关系分析以及该酶激酶活性新型旁侧抑制剂的结晶化。这类酶的小分子抑制剂因与激酶ATP结合位点相似而表现出对胰岛素受体ATP结合位点的交叉反应性。因此，竞争性激酶活性抑制剂也可能抑制胰岛素受体信号。由于作者描述的抑制剂在旁侧位点结合，它们在生理浓度下不会影响胰岛素受体信号传递。因此，这些小分子是用于分解活动和作为治疗起点的有用工具。
</ChineseVersionAnswer>
